NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth factor (FGF) 19 is a hormone that acts direct...

Full description

Bibliographic Details
Main Authors: Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, Andrew J. Muir, Lei Ling, Stephen J. Rossi, Alex M. DePaoli
Format: Article
Language:English
Published: Wiley 2018-09-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1209

Internet

https://doi.org/10.1002/hep4.1209

Similar Items